Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of ABBV-744 Alone or in Combination With Ruxolitinib or Navitoclax in Myelofibrosis
jRCT2031210007Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ABBV-744 in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (5 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With Adverse Events. Started Mar 2021; status: active, not recruiting.
02
Drugs
ABBV-744
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on jRCT2031210007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210007.